The integrase inhibitors elvitegravir (EVG) and dolutegravir (DTG) rapidly decrease the
plasma HIV-1 viral load, a key factor in the prevention of maternal-to-fetal transmission of …

Objective: To synthesize data on the pharmacokinetics and safety of dolutegravir and
elvitegravir in pregnant women living with HIV. Data Sources: A PubMed, EMBASE, Web of …

Objectives Data on fetal exposure to antiretroviral agents during pregnancy are important to
estimate their potential for prevention of mother-to-child transmission (PMTCT) and possible …

• Dolutegravir (DTG) is an integrase strand transfer inhibitor (INSTI) recommended for INSTI-
naïve and some INSTI-experienced patients with human immunodeficiency virus type 1 (HIV …

Background Antiretrovirals that achieve adequate concentrations in anatomical sites of
transmission are of interest for HIV prevention. A Phase I open-label pharmacokinetic (PK) …

Background• Dolutegravir (DTG) is an integrase strand inhibitor approved for the treatment
of HIV in adults and adolescents since 2013• Marketed as a single agent as Tivicay© and as …

Objective To determine the transplacental pharmacokinetics of the HIV integrase inhibitor
dolutegravir. Study design Maternal-to-fetal transfer across the term human placenta was …

Background Although antiretroviral regimens containing integrase inhibitors rapidly
suppress HIV viral load in non-pregnant adults, few published data from randomised …

Dolutegravir is currently recommended by the WHO as the preferred first-line treatment for
all people with HIV, including pregnant women. Estimates indicate that, by 2024, nearly 22 …

Data on placental transfer is lacking for the recent HIV integrase inhibitors, bictegravir and
cabotegravir, although their future use in pregnancy is to be expected. The objective of this …